Gene Mack's most recent trade in Gain Therapeutics Inc was a trade of 200,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gain Therapeutics Inc | Gene Mack | Director, CEO, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Gain Therapeutics Inc | Gene Mack | Director, CEO, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 271,325 | 271,325 | - | - | Stock Option (right to buy) | |
| Gain Therapeutics Inc | Gene Mack | CFO and Interim CEO | Purchase of securities on an exchange or from another person at price $ 1.01 per share. | 09 Aug 2024 | 14,400 | 14,400 | - | 1.0 | 14,544 | Common Stock |
| Gain Therapeutics Inc | Gene Mack | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) |